Search bioRxiv⌕ Search

Biology subjects

Ricos, M. G.

Publications and source records attributed to Ricos, M. G..

3 recordsLinked to original sources

IUPAC Consensus References Improve Short-Read Variant Detection in Clinically Challenging Regions: A Stratified Benchmarking Study with BurdenBench

MotivationReference bias depresses variant detection in low-mappability regions, segmental duplications and the major histocompatibility complex (MHC) -- precisely the regions of greatest clinical relevance. Existing benchmarks rely on aggregate precision, recall and F1 metrics that obscure the absolute true-positive and false-positive counts that determine laboratory workload. No study has systematically evaluated IUPAC consensus references for short-read whole-genome sequencing (WGS) variant calling across Genome in a Bottle (GIAB) stratifications, multiple allele-frequency thresholds and multiple variant callers. ResultsWe aligned 30x WGS from three GIAB samples to IUPAC consensus references (allele frequency [≥]10% and [≥]30%) using the ambiguity-aware aligner novoAlign, benchmarking against BWA-MEM/GRCh38 and novoAlign/GRCh38 baselines across BCFtools, FreeBayes and GATK HaplotypeCaller. SNV recall increased by 3.1-3.9 percentage points (pp) in low-mappability regions and 1.8-3.1 pp in segmental duplications; INDEL recall rose by 4.5-5.8 pp and 2.4-3.8 pp, respectively, with similar gains in the MHC and challenging medically relevant genes (CMRG). Decomposition analysis showed that the aligner change drove most INDEL gains, while IUPAC encoding contributed additional SNV-specific improvement. We introduce BurdenBench, an open-source framework that computes net benefit and region-size-normalised metrics directly from standard hap.py outputs, revealing divergent caller-specific trade-off profiles that are invisible to aggregate F1: FreeBayes showed the most favourable precision-recall balance in low-mappability regions, while GATK achieved positive net benefit in the MHC. A controlled comparison using an identical variant set showed severe recall and precision losses for SALT (a published SNP-aware dual-index aligner) across all three callers, supporting the value of preserving linear reference structure. Pan-human and population-specific consensuses performed within 0.2 pp of one another. All findings are descriptive and hypothesis-generating from three samples. Availability and implementationTo mitigate potential bias associated with software developed by an authors employer, primary hap.py outputs and derived burden metrics were independently verified by co-authors with no affiliation to that employer. BurdenBench (v1.0.0) is implemented in Python (pandas, numpy; Python [≥]3.7) and freely available under the MIT licence at https://github.com/akzam/BurdenBench, including raw hap.py outputs and an audit trail enabling independent recomputation without a novoAlign licence. novoAlign and novoUtil (version 4, Novocraft Technologies) are commercial software with no-cost academic trial licences. Contactleanne.dibbens@adelaide.edu.au Supplementary informationSupplementary tables, figures and methods are available online.

bioinformatics↗

Identification of new KCNT1-epilepsy drugs by in silico, cell and Drosophila modelling.

ObjectiveHyperactive KCNT1 potassium channels, caused by gain-of-function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug-resistant seizures and in cases with infantile onset, developmental regression can follow. KCNT1-related disorders include epilepsy of infancy with migrating focal seizures and sleep related hypermotor epilepsy. There are currently no effective treatments for KCNT1-epilepsies, but suppressing over-active channels poses a potential strategy. MethodsUsing KCNT1 channel structural data, we in silico screened a library of known drugs for those predicted to block the channel pore to reduce the current amplitude and inhibit channel activity. ResultsEight known drugs were investigated in vitro for their effects on patient-specific mutant KCNT1 channels, with four drugs showing significant reduction of K+ current amplitudes. The action of the four drugs was then analyzed in vivo and two were found to reduce the seizure phenotype in humanized Drosophila KCNT1-epilepsy models. InterpretationThis study identified two known drugs, antrafenine and nelfinavir mesylate, that reduce KCNT1 channel activity and reduce seizure activity in whole animals, suggesting their potential use as new treatments for KCNT1-epilepsy. The sequential in silico, in vitro and in vivo mechanism-based drug selection strategy used here may have broader application for other human disorders where a disease mechanism has been identified.

pharmacology and toxicology↗

Modelling human KCNT1-epilepsy in Drosophila: a seizure phenotype and drug responses

Mutations in the KCNT1 potassium channel cause severe forms of epilepsy which are resistant to current treatments. In vitro studies have shown that KCNT1-epilepsy mutations are gain of function, significantly increasing K+ current amplitudes. To investigate if Drosophila can be used to model human KCNT1 epilepsy, we generated Drosophila melanogaster lines carrying human KCNT1 with the patient mutation G288S, R398Q or R928C. Expression of each mutant channel in GABAergic neurons gave a seizure phenotype which was sensitive to drugs currently used to treat patients with KCNT1-epilepsy. Cannabidiol showed the greatest reduction of the seizure phenotype while some drugs increased the seizure phenotype. Our study shows that Drosophila can be used to model human KCNT1-epilepsy and potentially used as a tool to assess new treatments for KCNT1 epilepsy.

neuroscience↗